An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma

No clinically available biomarkers can predict pathological complete response (pCR) for esophageal squamous cell carcinomas (ESCCs) with neoadjuvant chemoradiotherapy (nCRT). Considering that antitumor immunity status is an important determinant for nCRT, we performed an integrative analysis of immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chaoqi, Zhang, Guochao, Sun, Nan, Zhang, Zhen, Xue, Liyan, Zhang, Zhihui, Yang, Haijun, Luo, Yuejun, Zheng, Xiaoli, Zhang, Yonglei, Yuan, Yufen, Lei, Ruixue, Yang, Zhaoyang, Zheng, Bo, Wang, Le, Che, Yun, Wang, Feng, Wang, Sihui, Gao, Shugeng, Xue, Qi, Zhang, Yi, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471268/
https://www.ncbi.nlm.nih.gov/pubmed/32883946
http://dx.doi.org/10.1038/s41392-020-00221-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471268/
https://www.ncbi.nlm.nih.gov/pubmed/32883946
http://dx.doi.org/10.1038/s41392-020-00221-8

Ejemplares similares